A NETWORK META-ANALYSIS COMPARING THE EFFICACY AND SAFETY OF CEFTOBIPROLE AND SELECTED COMPARATORS IN THE TREATMENT OF HOSPITAL-ACQUIRED PNEUMONIA
Author(s)
Pooley N1, Chadda S1, Madrigal AM2, Kuessner D3, Posthumus J4
1PHMR Associates, Newcastle upon Tyne, UK, 2PHMR Associates, London, UK, 3Basilea Pharmaceutica Ltd, Basel, Switzerland, 4Basilea Pharmaceutica International Ltd., Basel, Switzerland
OBJECTIVES: Hospital-acquired pneumonia (HAP) is a severe respiratory tract infection which develops more than 48h after hospital admission. Ceftobiprole, the active moiety of its prodrug ceftobiprole medocaril, is a new cephalosporin with bactericidal activity against a broad spectrum of pathogens including resistant bacteria such as methicillin-resistant S. aureus (MRSA), penicillin-resistant pneumococci and P. aeruginosa
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PRS4
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Respiratory-Related Disorders